Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH
Nina Shah, MD, touched on important abstracts being presented at the 2021 American Society of Hematology Annual Meeting.
Thomas G. Martin, MD, Discusses Abstracts He’s Eagerly Anticipating for Presentation at 2021 ASH
Thomas G. Martin, MD, spoke about different abstracts to be presented at ASH 2021.
Optimization of Genetic Testing for mCRPC
Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
Intriguing CLL Data From 2021 Conferences
Susan M. O’Brien, MD, discusses the important data from conferences in 2021 regarding chronic lymphocytic leukemia.
Sequencing Therapy for mCRPC
Daniel P. Petrylak, MD, leads the discussion on sequencing treatment for a patient with mCRPC, such as in case 2, who progresses on docetaxel therapy.
Successes and Challenges with Maintenance Therapy
Shilpa Gupta, MD and Jason Brown, MD discuss trials with successful or negative results with maintenance therapy.
Reflections on Future Treatment Strategies for HER2+ mBC
Experts close out their discussion on the management of HER2+ metastatic breast cancer by highlighting their hopes for future treatment strategies.
Patient Case #3: Sequencing Therapy and Monitoring Results
Centering their conversation on a patient case, experts discuss the sequencing and monitoring of therapy in patients with HER2+ metastatic breast cancer.
Audience Questions on Selecting Optimal Therapy for mBC
Panelists field questions from a live audience regarding the optimal selection of therapy for patients with metastatic breast cancer.
Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma
Nina Shah, MD, highlights some of the major takeaways in multiple myeloma from the 2021 European Hematology Association Congress.
Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
Nina Shah, MD, discusses breakthroughs in the treatment of multiple myeloma throughout the preceding year.
Major Breakthroughs in Treating Chronic Lymphocytic Leukemia
Susan M. O'Brien, MD, discusses breakthroughs in the treatment of chronic lymphocytic leukemia throughout the preceding year.
Second-Line Therapy for High-Risk Primary Myelofibrosis
Second-line treatment considerations for a 75-year-old man with high-risk primary myelofibrosis who was previously treated with ruxolitinib.
Second-Line Treatment Options for Myelofibrosis
Second-line therapies for myelofibrosis that are available or in the pipeline for use.
Patient Case 1: Discussion
The panel continues their conversation about the first patient case.
Patient Case 1: A 65-Year-Old Man With RCC
Toni Choueiri, MD, introduces the first patient case: a 65-year-old man with advanced-stage renal cell carcinoma.
Exciting Advances in the Therapeutic Space and Clinical Pearls for Treating Metastatic Prostate Cancer
Alicia Morgans, MD, MPH, lists several advances being made while treating metastatic prostate cancer and offers advice to clinicians who don’t see patients with the disease very often.
Sequencing Strategies for Metastatic Castration-Resistant Prostate Cancer Therapy
An expert examines sequencing strategies for the treatment of metastatic prostate cancer.
Updated Safety Data and Treatment Selection in nmCRPC
Dr Aaron Berger shares updated safety data on next-generation androgen receptor inhibitors and impact of safety profile on treatment selection in nmCRPC.
Adverse Events with Next-Generation Androgen Receptor Inhibitors in nmCRPC
Aaron Berger, MD, discusses adverse events with enzalutamide, apalutamide and darolutamide and their management.
